Personalized Probiotic Treatments for Irritable Bowel Syndrome
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07872514, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- McMaster University
- Trial code
- NCT07872514
- Record updated
- 13 October 2026
- Original description
Irritable bowel syndrome (IBS) is characterized by stomach pain and altered bowel habits. It affects about 5 million people in Canada. Doctors don't fully understand what causes IBS, so treatments often don't work well. Many patients say certain foods make their symptoms worse. This may be due to how gut bacteria break down food. Some bacteria produce harmful chemicals like histamine and lysophosphatidylcholine (LPC)/lysophosphatidic acid (LPA), which can cause pain and gut problems. These chemicals may affect about 35% of IBS patients. The goal is to find out which patients have these bacteria. Then, doctors can give them treatments that match their gut bacteria. This could help reduce symptoms and improve their lives. If the study is successful, it could change how we understand, diagnose, and treat IBS, leading to new treatments that focus on personalized microbiota-directed treatments targeting specific causative mechanisms.Read full original descriptionShow less
Deciphering the Role of Bacterial Histamine and Bioactive Phospholipids in IBS: Precision Medicine Pilot Study
Irritable bowel syndrome (IBS) is characterized by stomach pain and altered bowel habits. It affects about 5 million people in Canada. Doctors don't fully understand what causes IBS, so treatments often don't work well. Many patients say certain foods make their symptoms worse. This may be due to how gut bacteria break down food. Some bacteria produce harmful chemicals like histamine and lysophosphatidylcholine (LPC)/lysophosphatidic acid (LPA), which can cause pain and gut problems. These chemicals may affect about 35% of IBS patients. The goal is to find out which patients have these bacteria. Then, doctors can give them treatments that match their gut bacteria. This could help reduce symptoms and improve their lives. If the study is successful, it could change how we understand, diagnose, and treat IBS, leading to new treatments that focus on personalized microbiota-directed treatments targeting specific causative mechanisms.
Inclusion: Diagnosis of Irritable Bowel Syndrome; Willing and able to sign written informed consent; At least moderate IBS symptoms (IBS-SSS >175).
Exclusion: New IBS treatments (mediations, diet or psychotherapy) started within last 3 months. Medications will be allowed, provided the patient is on a stable dose for more than 3 months; Alcohol or drug abuse; Current organic gastrointestinal or autoimmune diseases, such as type 1 diabetes, celiac disease or inflammatory bowel disease; History of major gastrointestinal surgery (bariatric surgery, gastrectomy, colectomy, bowel resection); Connective tissue disease; Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection Participation in another dietary or pharmacological treatment study within the last 4 weeks; Use of antibiotics, antibiotics or probiotics, currently or within the last 4 weeks.